<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890888</url>
  </required_header>
  <id_info>
    <org_study_id>2014.011</org_study_id>
    <nct_id>NCT02890888</nct_id>
  </id_info>
  <brief_title>Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease</brief_title>
  <official_title>The Effect of Hyperbaric Oxygen on the Functional Connectivity of Resting State Neural Networks in Patients With Cerebral Small Vessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Hospital, Chesterfield, Missouri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's Hospital, Chesterfield, Missouri</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will have a Functional MRI before and after 10 hyperbaric Oxygen treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional MRI studies will be done before and 4-6 weeks after Hyperbaric Oxygen treatment to
      assess changes in connectivity of resting state neural networks. 10 hyperbaric treatments at
      2 atmospheres absolute for 1 hour at pressure will be administered. A review of symptoms and
      and thorough clinical neurological examination by an experienced neurologist familiar with
      these studies will be done before and 4-6 weeks after the hyperbaric treatments.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Depletion of Funds and Illness of principal investigator
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">October 25, 2017</completion_date>
  <primary_completion_date type="Actual">October 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average functional connectivity (fc) within the Default Mode Network and the Dorsal Attention Network will be obtained by resting state network (rsn) functional connectivity (rsnfc) MRI.</measure>
    <time_frame>Change in baseline rsnfc before and 4 weeks after hyperbaric oxygen</time_frame>
    <description>Functional connectivity MRI of resting state neural networks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cerebral Small Vessel Diseases</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hyperbaric oxygen treatment</intervention_name>
    <description>Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week</description>
    <arm_group_label>Hyperbaric oxygen treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  White Matter Hyperintensities on MRI

          -  2 or more neurological symptoms or impairments e.g. gait disturbances, disequilibrium,
             cognitive decline, dysmetria, hyper-rflexia

        Exclusion Criteria:

          -  Contraindication to hyperbaric oxygen treatment e.g. pulmonary emphysema, seizure
             disorder

          -  major eustachian tube dysfunction

          -  stroke with previous 6 months

          -  extreme cognitive impairment

          -  major depression

          -  history of migraine, electroshock therapy, brain irradiation, brain tumor, head trauma

          -  other uncontrolled co-morbidities, e.g. diabetes, renal or hepatic dysfunction,
             hypertension, thyroid disorders, carotid artery stenosis (&gt;70%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Institute of Radiology/Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Luke's Hospital, Chesterfield, Missouri</investigator_affiliation>
    <investigator_full_name>John Davidson</investigator_full_name>
    <investigator_title>Director, Division of Hyperbaric Medicine</investigator_title>
  </responsible_party>
  <keyword>small vessel disease of the brain</keyword>
  <keyword>hyperbaric oxygen</keyword>
  <keyword>functional connectivity MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

